Akebia Therapeutics, Inc. has focused on expanding its product portfolio and market presence through strategic partnerships and licensing agreements. The company has entered into a license agreement with Cyclerion Therapeutics to develop and commercialize praliciguat, an investigational oral soluble guanylate cyclase stimulator, and amended this agreement to control all clinical and commercial manufacturing. Additionally, Akebia has secured commercial supply agreements for Vafseo with dialysis organizations covering nearly 100% of U.S. dialysis patients, and has partnered with Medice and Mitsubishi Tanabe Pharma Corporation for international commercialization.